Loading...
Docoh

Yumanity Therapeutics (YMTX)

Utility
Compounds and Uses Thereof
22 Sep 22
The present invention features compounds useful in the treatment of neurological disorders.
Bertrand LE BOURDONNEC, Matthew LUCAS, Kerem OZBOYA, Bhaumik PANDYA, Daniel TARDIFF, Parcharee TIVITMAHAISOON, Iwona WRONA
Filed: 22 Sep 20
Utility
Compositions and Methods for the Treatment and Prevention of Neurological Disorders
14 Apr 22
The invention provides compositions and methods for treating neurological disorders, such as amyotrophic lateral sclerosis, frontotemporal degeneration, and Alzheimer's disease, among others.
Rebecca ARON, Bhaumik PANDYA, Daniel TARDIFF, Jeff PIOTROWSKI, Matthew LUCAS, Bertrand LE BOURDONNEC, Kenneth RHODES, Robert SCANNEVIN
Filed: 23 Dec 21
Utility
Methods for the Treatment of Neurological Disorders
10 Feb 22
The present disclosure provides compounds and methods useful in the treatment of neurological disorders.
Benjamin Matteson VINCENT, Daniel Forrest TARDIFF, Jeff Scott PIOTROWSKI, Eric SOLIS, Robert Hughie SCANNEVIN, Chee-Yeun CHUNG, Rebecca ARON, Bertrand LE BOURDONNEC, Matthew LUCAS, Kenneth RHODES
Filed: 9 Apr 21
Utility
Compositions and methods for the treatment and prevention of neurological disorders
8 Feb 22
The invention provides compositions and methods for treating neurological disorders, such as amyotrophic lateral sclerosis, frontotemporal degeneration, and Alzheimer's disease, among others.
Rebecca Aron, Bhaumik Pandya, Daniel Tardiff, Jeff Piotrowski, Matthew Lucas, Bertrand Le Bourdonnec, Kenneth Rhodes, Robert Scannevin
Filed: 21 Jun 19
Utility
Compounds and Uses Thereof
13 May 21
The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer.
Iwona WRONA, Kerem OZBOYA, Matthew LUCAS, Bhaumik PANDYA, Bertrand LE BOURDONNEC
Filed: 24 Jan 20
Utility
Methods for the treatment of neurological disorders
13 Apr 21
The present disclosure provides compounds and methods useful in the treatment of neurological disorders.
Benjamin Vincent, Daniel Tardiff, Jeff Piotrowski, Eric Solis, Robert Scannevin, Chee-Yeun Chung, Rebecca Aron, Bertrand Le Bourdonnec, Matthew Lucas, Kenneth Rhodes
Filed: 5 Jan 18
Utility
Compounds and uses thereof
16 Feb 21
The present invention features compounds useful in the treatment of neurological disorders.
Iwona Wrona, Parcharee Tivitmahaisoon, Daniel Tardiff, Bhaumik Pandya, Kerem Ozboya, Matthew Lucas, Bertrand Le Bourdonnec
Filed: 24 Apr 19
Utility
Compounds, compositions, and methods for increasing CFTR activity
26 Jan 21
The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
Daniel Parks, Cecilia M. Bastos, Matthew Cullen, Benito Munoz
Filed: 21 Jun 17
Utility
Compounds, Compositions, and Methods for Modulating CFTR
9 Dec 20
The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.
Benito Munoz, Cecilia M. Bastos, Daniel Parks, David Kombo
Filed: 16 Dec 19
Utility
Compounds, Compositions, and Methods of Increasing CFTR Activity
18 Nov 20
The present disclosure features compounds such as those having the Formulae (I) and (II), which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
Benito Munoz, Cecilia M. Bastos, John Miller
Filed: 10 Dec 19
Utility
Methods of Quantifying CFTR Protein Expression
28 Oct 20
The present disclosure is directed in part to methods of detecting and quantifying cystic fibrosis transmembrane conductance regulator (CFTR) protein expression in a sample, e.g., by an Enzyme-Linked Immunosorbent Assay (ELISA) or an AlphaLISA®, a fusion polypeptide capable of binding to a capture antibody and a detection antibody, and a kit for performing an ELISA or an AlphaLISA® to detect CFTR protein.
Daniel Kanmert, Adriana Villella
Filed: 27 Dec 18
Utility
Proteasome Activity Enhancing Compounds
30 Sep 20
The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
Matthew Cullen, Sheila Hauck, Bolin Geng, Megan Foley, Cecilia M. Bastos, Benito Munoz, Markus Haeberlein, Bradley Tait
Filed: 14 Jun 20
Utility
Proteostasis Regulators
23 Sep 20
The present invention is directed to compounds having the Formulae (Ia-Ie), (II), (IIIa-IIId), (IVa-IVc), (Va-Vb), (VIa-VIe), (VII), (VIIIa-VIIIc), and (IX), pharmaceutically acceptable salts, prodrugs and solvates thereof, compositions of any of thereof and methods for the treatment of a condition associated with a dysfunction in proteostasis comprising an effective amount of these compounds.
Megan Foley, Bradley Tait, Matthew Cullen
Filed: 20 Nov 19
Utility
Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
10 Aug 20
The present disclosure is based, in part, on the discovery that disclosed compounds such as those having Formula (IVa), (Va), (IV), or (V) can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
Cecilia M. Bastos, Benito Munoz, Bradley Tait
Filed: 22 Dec 15
Utility
Compounds, compositions, and methods for increasing CFTR activity
10 Aug 20
The present disclosure features disclosed compounds which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
Cecilia M. Bastos, Benito Munoz, Bradley Tait
Filed: 13 Nov 18
Utility
Compounds, Compositions, and Methods for Increasing CFTR Activity
17 Jun 20
The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
Cecilia M. Bastos, Benito Munoz, Bradley Tait
Filed: 11 Jul 19
Utility
Compounds, compositions, and methods for modulating CFTR
25 May 20
The present disclosure is directed to disclosed compounds that modulate e.g., address underlying defects in cellular processing of CFTR activity.
Benito Munoz, Daniel Parks, Cecilia M. Bastos
Filed: 6 Apr 17
Utility
4-SULFONYLAMINOCARBONYLQUINOLINE Derivatives for Increasing CFTR Activity
19 Feb 20
The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.
Daniel PARKS, Benito MUNOZ
Filed: 29 Apr 18
Utility
Compounds, compositions, and methods of increasing CFTR activity
3 Feb 20
The present disclosure features compounds such as those having the Formulae (I) and (II), which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
Benito Munoz, Cecilia M. Bastos, John Miller
Filed: 24 Jul 16
Utility
Compounds, compositions, and methods for modulating CFTR
3 Feb 20
The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.
Benito Munoz, Cecilia M. Bastos, Daniel Parks, David Kombo
Filed: 5 Oct 16
Patents are sorted by USPTO publication date, most recent first